a Department of Clinical Nutrition , School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences , Tehran , Iran.
b Department of Drug & Food Control , Faculty of Pharmacy and Pharmaceutical Quality Assurance Research Centre, Tehran University of Medical Sciences , Tehran , Iran.
J Am Coll Nutr. 2017 Sep-Oct;36(7):497-506. doi: 10.1080/07315724.2017.1318724. Epub 2017 Jun 19.
The development of alternative approaches to prevent and/or treat osteoporosis, as a chronic progressive bone disease, is being considered currently. Among dietary supplements, probiotics may have favorable effects on bone metabolism. Therefore, the aim of this study was to evaluate the effects of a multispecies probiotic supplementation on bone biomarkers and bone density in osteopenic postmenopausal women.
This randomized double-blind placebo-controlled clinical trial was performed on 50 patients with osteopenia aged 50-72 years. Participants were randomly assigned to take either a multispecies probiotic supplement (GeriLact; n = 25) or placebo (n = 25) for 6 months. GeriLact contains 7 probiotic bacteria species. Participants received 500 mg Ca plus 200 IU vitamin D daily. Bone mineral density (BMD) of lumbar spine and total hip and blood biomarkers including bone-specific alkaline phosphatase (BALP), osteocalcin (OC), collagen type 1 cross-linked C-telopeptide (CTX), deoxypyridinoline (DPD), parathyroid hormone (PTH), 25-OH vitamin D, and serum pro-inflammatory cytokines (tumor necrosis factor [TNF]-α and interleukin [IL]-1β) were assessed at baseline and at the end of the study.
The multispecies probiotic significantly decreased BALP (p = 0.03) and CTX (p = 0.04) levels in comparison with the control group but had no effect on BMD of the spine and total hip. Moreover, there was a statistically significant decrease in serum PTH (p = 0.01) and TNF-α (p = 0.02) in the intervention group compared to the placebo group.
These results may suggest the favorable effects of the multispecies probiotic supplementation for 6 months on bone health in postmenopausal women due to slowing down the rate of bone turnover.
目前，人们正在考虑寻找替代方法来预防和/或治疗骨质疏松症，这是一种慢性进行性骨疾病。在膳食补充剂中，益生菌可能对骨骼代谢有有益的影响。因此，本研究旨在评估多菌种益生菌补充剂对骨质疏松绝经后妇女的骨生物标志物和骨密度的影响。
这项随机双盲安慰剂对照临床试验在 50 名年龄在 50-72 岁之间的骨质疏松绝经后妇女中进行。参与者被随机分为多菌种益生菌补充剂（GeriLact；n=25）或安慰剂（n=25）组，服用时间为 6 个月。GeriLact 含有 7 种益生菌。参与者每天接受 500mg Ca 和 200IU 维生素 D。在基线和研究结束时评估腰椎和全髋骨矿物质密度（BMD）以及血液生物标志物，包括骨碱性磷酸酶（BALP）、骨钙素（OC）、I 型胶原交联 C 端肽（CTX）、脱氧吡啶啉（DPD）、甲状旁腺激素（PTH）、25-羟维生素 D 和血清促炎细胞因子（肿瘤坏死因子[TNF]-α 和白细胞介素[IL]-1β）。
与对照组相比，多菌种益生菌显著降低了 BALP（p=0.03）和 CTX（p=0.04）水平，但对脊柱和全髋骨密度没有影响。此外，与安慰剂组相比，干预组血清 PTH（p=0.01）和 TNF-α（p=0.02）显著下降。
这些结果表明，多菌种益生菌补充剂在 6 个月内对绝经后妇女的骨骼健康有有益的影响，可能是通过减缓骨转换率来实现的。
